[1]张伟 权大君 向杰 黄从新.人源性诱导多潜能干细胞向心肌细胞分化的实验研究[J].心血管病学进展,2020,(7):753-758.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.020]
 ZHANG Wei,QUAN Dajun,XIANG Jie,et al.Experimental Research on Differentiation of Human Induced Pluripotent Stem Cells into Cardiomyocytes[J].Advances in Cardiovascular Diseases,2020,(7):753-758.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.020]
点击复制

人源性诱导多潜能干细胞向心肌细胞分化的实验研究()
分享到:

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2020年7期
页码:
753-758
栏目:
出版日期:
2020-07-25

文章信息/Info

Title:
Experimental Research on Differentiation of Human Induced Pluripotent Stem Cells into Cardiomyocytes
作者:
张伟 权大君 向杰 黄从新
(武汉大学人民医院心内科 武汉大学心血管病研究所 心血管病湖北重点实验室,湖北 武汉 430060 )
Author(s):
ZHANG WeiQUAN DajunXIANG JieHUANG Congxin
(Department of Cardiology, Renmin Hospital of Wuhan University,Cardiovascular Research Institute,Wuhan University, Hubei Key Laboratory of Cardiology,Wuhan 430060,Hubei,China)?/html>
关键词:
人源性诱导多潜能干细胞Wnt信号通路心肌细胞动作电位
Keywords:
Human induced pluripotent stem cells Wnt signal pathway Cardiomyocytes Action potential
DOI:
10.16806/j.cnki.issn.1004-3934.2020.07.020
摘要:
目的 探究通过阶段性调控经典Wnt信号通路促使人源性诱导多潜能干细胞(hiPSCs)向心肌细胞分化。方法 采用阶段性激活或抑制Wnt信号通路的方案使人尿路上皮细胞来源的多潜能干细胞(U1细胞系)定向分化为心肌细胞(hiPSC-CMs);在分化第14天,采用流式细胞术检测U1细胞向心肌细胞分化的效率;利用免疫细胞化学检测心肌细胞肌钙蛋白表达;通过激光扫描共聚焦荧光显微镜检测hiPSC-CMs的钙离子活动;利用全细胞膜片钳技术记录hiPSC-CMs的电生理特性。结果 U1细胞系向hiPSC-CMs分化的效率为(88±3)%;全细胞膜片钳技术记录的动作电位特征显示hiPSC-CMs可分为心室肌样细胞、心房肌样细胞和窦房结样细胞,其中主要是心室肌样细胞。窦房结样细胞的比例、动作电位时程、动作电位幅度及最大去极化速率均明显小于心室肌样细胞和心房肌样细胞。结论 阶段性调控Wnt信号通路能促使hiPSCs定向分化为hiPSC-CMs,并且hiPSC-CMs具有哺乳动物心肌细胞相似的电生理特征。
Abstract:
Objective To promote the differentiation of human induced pluripotent stem cells(hiPSCs) into cardiomyocytes through the manipulation of the canonical Wnt signaling pathway. Methods hiPSCs(U1 cell lines) derived from undifferentiated healthy adult urothelium cells were differentiated into cardiomyocytes by staged activation or inhibition of the Wnt signaling pathway. On the 14th day of differentiation, flow cytometry was used to detect the differentiation efficiency of U1 cell lines into cardiomyocytes. Immunocytochemistry was utilized to detect cardiac troponin T expression in cardiomyocytes. The calcium activity of hiPSC-CMs was recorded by laser scanning confocal fluorescence microscopy. The electrophysiological characteristics of hiPSC-CMs were detected by whole cell patch clamp techniques. Results The efficiency of U1 cell line differentiation to hiPSC-CMs was (88±3)%. Action potential characteristics recorded by whole-cell patch-clamp techniques demonstrated hiPSC-CMs could be divided into ventricular-like cardiomyocytes, atrial-like cardiomyocytes and sinoatrial node-like pacemaker cells, but mainly ventricular-like cardiomyocytes. The proportion, action potential duration, action potential amplitude and maximum depolarization rate of sinoatrial node-like pacemaker cells were significantly lower than those of ventricular-like cardiomyocytes and atrial-like cardiomyocytes. Conclusions The phased modulation of Wnt signaling pathway could induce hiPSCs to differentiate into hiPSC-CMs with high differentiation efficiency, and hiPSC-CMs have similar electrophysiological characteristics with mammalian cardiomyocytes.

参考文献/References:

[1]梁小婷.干细胞治疗心力衰竭临床研究进展[J].心血管病学进展,2018, 39(3) :379-384.

[2] Mummery CL. Perspectives on the use of human induced pluripotent stem cell-derived cardiomyocytes in biomedical research[J]. Stem Cell Reports, 2018,11(6):1306-1311.

[3] Blau HM, Daley GQ. Stem cells in the treatment of disease[J]. N Engl J Med, 2019,380(18):1748-1760.

[4] Yoshida Y, Yamanaka S. Induced pluripotent stem cells 10 years later: for cardiac applications[J]. Circ Res, 2017,120(12):1958-1968.

[5] Lian X, Zhang J, Azarin SM, et al. Directed cardiomyocyte differentiation from human pluripotent stem cells by modulating Wnt/βeta-catenin signaling under fully defined conditions[J]. Nat Protoc,2013,8(1):162-175.

[6] Mummery CL, Zhang J, Ng ES, et al. Differentiation of human embryonic stem cells and induced pluripotent stem cells to cardiomyocytes: a methods overview[J]. Circ Res, 2012,111(3):344-58.

[7] Lian X, Hsiao C, Wilson G, et al. Robust cardiomyocyte differentiation from human pluripotent stem cells via temporal modulation of canonical Wnt signaling[J]. Proc Natl Acad Sci U S A,2012,109(27):E1848- E1857.

[8] Rowe RG, Daley GQ. Induced pluripotent stem cells in disease modelling and drug discovery[J]. Nat Rev Genet,2019,20(7):377-388.

[9] Sharma A, McKeithan WL, Serrano R, et al. Use of human induced pluripotent stem cell-derived cardiomyocytes to assess drug cardiotoxicity[J]. Nat Protoc, 2018,13(12):3018-3041.

[10] Ross SB, Fraser ST, Semsarian C. Induced pluripotent stem cell technology and inherited arrhythmia syndromes[J]. Heart Rhythm,2018,15(1):137-144.

[11] Liu C, Oikonomopoulos A, Sayed N, et al. Modeling human diseases with induced pluripotent stem cells:from 2D to 3D and beyond[J]. Development, 2018,145(5):dev156166.

[12] Nugraha B, Buono MF, von Boehmer L, et al. Human cardiac organoids for disease modeling[J]. Clin Pharmacol Ther, 2019,105(1):79-85.

[13] Soldner F, Jaenisch R. Stem cells, genome editing, and the path to translational medicine[J]. Cell,2018,175(3):615-632.

[14] Protze SI, Liu J, Nussinovitch U, et al. Sinoatrial node cardiomyocytes derived from human pluripotent cells function as a biological pacemaker[J]. Nat Biotechnol, 2017,35(1):56-68.

[15] Lee JH, Protze SI, Laksman Z, et al. Human pluripotent stem cell-derived atrial and ventricular cardiomyocytes develop from distinct mesoderm populations[J]. Cell Stem Cell, 2017, 21(2):179-194,e4.

[16] Tu C, Chao BS, Wu JC. Strategies for improving the maturity of human induced pluripotent stem cell-derived cardiomyocytes[J]. Circ Res, 2018,123(5):512-514.

[17] Jiang Y, Park P, Hong SM, et al. Maturation of cardiomyocytes derived from human pluripotent stem cells:current strategies and limitations[J]. Mol Cells, 2018,41(7):613-621.

相似文献/References:

[1]孔凡玲 刘慧 程维礼 张莱 陶琴 张郁青.Sfrp5与心血管疾病的相关性研究进展[J].心血管病学进展,2023,(10):939.[doi:10.16806/j.cnki.issn.1004-3934.2023.10.017]
 KONG FanlingLIU HuiCHENG WeiliZHANG LaiTAO QinZHANG Yuqing.Progress of the Association of Sfrp5 with Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2023,(7):939.[doi:10.16806/j.cnki.issn.1004-3934.2023.10.017]

备注/Memo

备注/Memo:
基金项目:湖北省技术创新专项(2016ACA153)基金项目:湖北省技术创新专项(2016ACA153
更新日期/Last Update: 2020-10-10